BACKGROUND AND PURPOSE: The PAR(2) receptors are involved in chronic arthritis by mechanisms that are as yet unclear. Here, we examined PAR(2) activation in the rat knee joint. EXPERIMENTAL APPROACH: PAR(2) in rat knee joint dorsal root ganglia (DRG) cells at L3-L5, retrogradely labelled with Fluoro-gold (FG) were demonstrated immunohistochemically. Electrophysiological recordings from knee joint nerve fibres in urethane anaesthetized Wistar rats assessed the effects of stimulating joint PAR(2) with its activating peptide, 2-furoyl-LIGRLO-NH(2) (1-100 nmol·100 μL(-1) , via close intra-arterial injection). Fibre firing rate was recorded during joint rotations before and 15 min after administration of PAR(2) activating peptide or control peptide. Leukocyte kinetics in the synovial vasculature upon PAR(2) activation were followed by intravital microscopy for 60 min after perfusion of 2-furoyl-LIGRLO-NH(2) or control peptide. Roles for transient receptor potential vanilloid-1 (TRPV1) or neurokinin-1 (NK(1) ) receptors in the PAR(2) responses were assessed using the selective antagonists, SB366791 and RP67580 respectively. KEY RESULTS: PAR(2) were expressed in 59 ± 5% of FG-positive DRG cells; 100 nmol 2-furoyl-LIGRLO-NH(2) increased joint fibre firing rate during normal and noxious rotation, maximal at 3 min (normal; 110 ± 43%, noxious; 90 ± 31%). 2-Furoyl-LIGRLO-NH(2) also significantly increased leukocyte rolling and adhesion over 60 min. All these effects were blocked by pre-treatment with SB366791 and RP67580 (P < 0.05 compared with 2-furoyl-LIGRLO-NH(2) alone). CONCLUSIONS AND IMPLICATIONS: PAR(2) receptors play an acute inflammatory role in the knee joint via TRPV1- and NK(1) -dependent mechanisms involving both PAR(2) -mediated neuronal sensitization and leukocyte trafficking.
BACKGROUND AND PURPOSE: The PAR(2) receptors are involved in chronic arthritis by mechanisms that are as yet unclear. Here, we examined PAR(2) activation in the rat knee joint. EXPERIMENTAL APPROACH: PAR(2) in rat knee joint dorsal root ganglia (DRG) cells at L3-L5, retrogradely labelled with Fluoro-gold (FG) were demonstrated immunohistochemically. Electrophysiological recordings from knee joint nerve fibres in urethane anaesthetized Wistar rats assessed the effects of stimulating joint PAR(2) with its activating peptide, 2-furoyl-LIGRLO-NH(2) (1-100 nmol·100 μL(-1) , via close intra-arterial injection). Fibre firing rate was recorded during joint rotations before and 15 min after administration of PAR(2) activating peptide or control peptide. Leukocyte kinetics in the synovial vasculature upon PAR(2) activation were followed by intravital microscopy for 60 min after perfusion of 2-furoyl-LIGRLO-NH(2) or control peptide. Roles for transient receptor potential vanilloid-1 (TRPV1) or neurokinin-1 (NK(1) ) receptors in the PAR(2) responses were assessed using the selective antagonists, SB366791 and RP67580 respectively. KEY RESULTS:PAR(2) were expressed in 59 ± 5% of FG-positive DRG cells; 100 nmol 2-furoyl-LIGRLO-NH(2) increased joint fibre firing rate during normal and noxious rotation, maximal at 3 min (normal; 110 ± 43%, noxious; 90 ± 31%). 2-Furoyl-LIGRLO-NH(2) also significantly increased leukocyte rolling and adhesion over 60 min. All these effects were blocked by pre-treatment with SB366791 and RP67580 (P < 0.05 compared with 2-furoyl-LIGRLO-NH(2) alone). CONCLUSIONS AND IMPLICATIONS: PAR(2) receptors play an acute inflammatory role in the knee joint via TRPV1- and NK(1) -dependent mechanisms involving both PAR(2) -mediated neuronal sensitization and leukocyte trafficking.
Authors: N Vergnolle; N W Bunnett; K A Sharkey; V Brussee; S J Compton; E F Grady; G Cirino; N Gerard; A I Basbaum; P Andrade-Gordon; M D Hollenberg; J L Wallace Journal: Nat Med Date: 2001-07 Impact factor: 53.440
Authors: J B Davis; J Gray; M J Gunthorpe; J P Hatcher; P T Davey; P Overend; M H Harries; J Latcham; C Clapham; K Atkinson; S A Hughes; K Rance; E Grau; A J Harper; P L Pugh; D C Rogers; S Bingham; A Randall; S A Sheardown Journal: Nature Date: 2000-05-11 Impact factor: 49.962
Authors: Mark N Adams; Rithwik Ramachandran; Mei-Kwan Yau; Jacky Y Suen; David P Fairlie; Morley D Hollenberg; John D Hooper Journal: Pharmacol Ther Date: 2011-01-26 Impact factor: 12.310
Authors: J R Lindner; M L Kahn; S R Coughlin; G R Sambrano; E Schauble; D Bernstein; D Foy; A Hafezi-Moghadam; K Ley Journal: J Immunol Date: 2000-12-01 Impact factor: 5.422
Authors: M J Caterina; A Leffler; A B Malmberg; W J Martin; J Trafton; K R Petersen-Zeitz; M Koltzenburg; A I Basbaum; D Julius Journal: Science Date: 2000-04-14 Impact factor: 47.728
Authors: Zs Helyes; K Sándor; E Borbély; V Tékus; E Pintér; K Elekes; D M Tóth; J Szolcsányi; J J McDougall Journal: Eur J Pain Date: 2009-08-15 Impact factor: 3.931
Authors: Éva Borbély; Katalin Sándor; Adrienn Markovics; Ágnes Kemény; Erika Pintér; János Szolcsányi; John P Quinn; Jason J McDougall; Zsuzsanna Helyes Journal: Inflamm Res Date: 2016-06-01 Impact factor: 4.575